Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

6 treatments under study, led by Gadolinium

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 25/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed with results

Key Signals

2 with results100% success

Data Visualizations

Phase Distribution

2Total
Not Applicable (1)
Early Phase 1 (1)

Trial Status

Completed2
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT04053868Not ApplicableCompleted

Evaluating the Comparative Pharmacokinetics of Nicotine After Administration Via JUUL or Tobacco Cigarettes

NCT02783768Early Phase 1Completed

Ventilation and Pulmonary Endothelium Toxicities of E-cigarettes: A Randomized Crossover Pilot Study

NCT03153228UnknownPrimary

Acute Response to Cigarette and E-cigarette Smoking Assesed in Exhaled Breath Condensate in Healthy Smokers of Traditional and E-cigarettes

Showing all 3 trials

Research Network

Common Treatments

  • Gadolinium1
  • Juul1
  • Sham1
  • Hyperpolarized 3helium1
  • Tobacco1

Active Sponsors

  • Medical University of Warsaw1
  • University of California, San Francisco1
  • Columbia University1
  • National Institute on Drug Abuse (NIDA)1

Top Investigators

Related Conditions

  • Tobacco Smoking1
  • Nicotine Administration Dosage1
  • Vaping1
  • Pulmonary Disease Chronic Obstructive1
  • Eliquid1

Activity Timeline